Clinical Trials Logo

Clinical Trial Summary

This is a multicenter, open-label, single arm phase II non-randomized study of dasatinib in which subjects with systemic mastocytosis (SM) will be treated with a continuous regimen of dasatinib.

Upon completion of a treatment induction period, subjects will be treated with dasatinib at a dose of 100 mg per os (OS) once daily (QD).


Clinical Trial Description

Dasatinib may have clinical efficacy and is safe in subjects with SM. This Multicenter, open-label, single arm Phase II study will investigate the clinical response rate in terms of both B/C findings and mediator-related symptoms.

30 adult patients will be treated with a continuous regimen of dasatinib at a starting dose of 20 mg administered orally (PO) once daily (QD), that can be escalated up to 100 mg QD at the end of Week 3. Upon completion of a treatment induction period, subjects will be treated with dasatinib at a daily dose of 100 mg PO QD. Patients will remain on dasatinib treatment for 12 months unless disease progression, unacceptable toxicity or other reasons determine treatment discontinuation. Subjects may continue receiving protocol therapy as long as they are deriving a clinical benefit.

Additionally, all subjects will be followed until disease progression, death, or 12 months beyond discontinuation from study treatment.

The total duration of the study is estimated to 36 months. ;


Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00979160
Study type Interventional
Source Federico II University
Contact Massimo Triggiani, prof.
Phone +390817462218
Email triggian@unina.it
Status Not yet recruiting
Phase Phase 2
Start date November 2009
Completion date December 2012

See also
  Status Clinical Trial Phase
Completed NCT01807598 - Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia Phase 2
Completed NCT00171912 - Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes Phase 2
Completed NCT02441166 - Diagnostic Value of Bone Marrow Tryptase in Systemic Mastocytosis N/A
Withdrawn NCT03739606 - Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Phase 2
Active, not recruiting NCT04681105 - Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies Phase 1
Recruiting NCT01602939 - Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis Phase 2/Phase 3
Completed NCT03401060 - Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis Phase 3
Terminated NCT02415608 - Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis Phase 2
Completed NCT02478957 - Treatment of Indolent Systemic Mastocytosis With PA101 Phase 2
Terminated NCT00918931 - Obatoclax for Systemic Mastocytosis Phase 2
Completed NCT00493129 - Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) Phase 2
Completed NCT01297777 - Imatinib in KIT-negative Systemic Mastocytosis Phase 4
Terminated NCT03214666 - GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies Phase 1/Phase 2
Completed NCT01334996 - Use of Tamoxifen in Systemic Mastocytosis
Completed NCT00449748 - Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis Phase 2
Completed NCT00109707 - A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies Phase 1/Phase 2